Turn Therapeutics (TTRX) Debt Ratio (2025 - 2026)

Turn Therapeutics (TTRX) recorded quarterly Debt Ratio of 0.47 in Q1 2026, up 87.49% quarter-over-quarter from 0.25 in Q4 2025.

Turn Therapeutics (TTRX) Debt Ratio (2025 - 2026) Analysis & Trends

Turn Therapeutics' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.47 for Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.47; the TTM figure through Mar 2026 stood at 0.47 (changed N/A YoY), while the FY2025 annual figure was 0.25, changed N/A from the prior year.
Debt Ratio was 0.47 for Q1 2026 at Turn Therapeutics, up from 0.25 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.47 in Q1 2026 to a low of 0.25 in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.18
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Turn Therapeutics	175.38 Mn	175.38 Mn	-	0.47

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.47
Dec 31, 2025	0.25